Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Jump to: Article
Number of items: 10.

Article

Emery, P orcid.org/0000-0002-7429-8482, Burmester, GR, Bykerk, VP et al. (4 more authors) (2019) Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. RMD Open, 5 (1). e000840. ISSN 2056-5933

Bykerk, VP, Burmester, GR, Combe, BG et al. (4 more authors) (2019) Correction to: On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. Rheumatology International. ISSN 0172-8172

Bykerk, VP, Burmester, GR, Combe, BG et al. (4 more authors) (2018) On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. Rheumatology International, 38 (12). pp. 2225-2231. ISSN 0172-8172

Johnson, SR, Soowamber, ML, Fransen, J et al. (34 more authors) (2018) There is a need for new systemic sclerosis subset criteria. A content analytic approach. Scandinavian Journal of Rheumatology, 47 (1). pp. 62-70. ISSN 0300-9742

Weinblatt, ME, Bingham, CO, Burmester, G-R et al. (9 more authors) (2017) A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis and Rheumatology, 69 (10). pp. 1937-1948. ISSN 2326-5191

Emery, P, Bingham III, CO, Burmester, GR et al. (11 more authors) (2017) Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Annals of the Rheumatic Diseases, 76 (1). pp. 96-104. ISSN 0003-4967

Bykerk, VP, Emery, P, Weinblatt, ME et al. (7 more authors) (2016) PMS82 – Clinical Responses and Improvements in Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol. Value in Health. ISSN 1098-3015

Emery, P, Bingham III, CO, Burmester, GR et al. (11 more authors) (2016) Response to: ‘Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!’ by Boers. Annals of the Rheumatic Diseases, 75 (10). e69. ISSN 0003-4967

Peterfy, C, Burmester, GR, Bykerk, VP et al. (7 more authors) (2016) Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Annals of the Rheumatic Diseases, 75 (8). pp. 1501-1505. ISSN 0003-4967

Combe, B, Furst, DE, Keystone, EC et al. (5 more authors) (2016) Certolizumab Pegol Remains an Equally Efficacious Treatment of Rheumatoid Arthritis Over a Range of Background Methotrexate Regimens. Arthritis Care and Research, 68 (3). pp. 299-307. ISSN 2151-464X

This list was generated on Sat Oct 12 20:07:04 2019 BST.